Furthermore, a retrospective study including MM patients receiving bi-specific antibody therapies (e.g., BCMA, GPRC5D and FCRH5) showed a correlation with all-grade infections (13–76%). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.